by ASH Publications
Evidence suggests ciltacabtagene autoleucel (cilta-cel) generates a durable response in patients with relapsed/refractory multiple myeloma, even those who would not have qualified for...
by Blood Advances
Findings from the Phase 3 AURIGA trial support the use of lenalidomide plus daratumumab (D-R) over lenalidomide alone (R) as post-transplant maintenance therapy for patients with newly diagnosed...
by Blood Advances
Researchers say pharmacological attenuation of CDC42, a protein coding gene, effectively addresses bone-related problems caused by cytotoxic conditioning required before hematopoietic stem cell...
by ASTCT Talks
Welcome to the first installment of an exclusive 8-part ASTCT Talks series, supported by an educational grant from Sanofi US.
by Dr. Corey Cutler, MD, MPH
In the October President's Message, Dr. Corey Cutler, MD, MPH, reflects on the impactful moments from the recent Clinical Education Conference in Saint Louis, where transplant and cell therapy...
by Nature
Researchers believe treatment with an antibacterial enzyme specific to Enterococcus faecalis may provide prophylaxis against acute graft-versus-host disease (aGVHD).